


Tipo	Periódico
Título	Antitumor activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling in patients with B-cell non-Hodgkin lymphoma
Autores	Ribeiro, Marcelo Lima; Reyes-Garau, Diana ; Vinyoles, Meritxell ; Profitos-Peleja, Nuria ; Santos, Juliana Carvalho ; Armengol, Marc ; Fernández-Serrano, Miranda ; Sedo Mor, Alicia ; Bech-Serra, Joan Josep ; Bledua, Pedro ; Musulen, Eva ; De La Torre, Carolina ; Miskin, Hari P. ; Esteller, Manel ; Bosch, Francesc ; Menéndez, Pablo ; Normant, Emmanuel ; Roué, Gaël
Autor (es) USF	Ribeiro, Marcelo Lima
Autores Internacionais	Reyes-Garau, Diana ; Vinyoles, Meritxell ; Profitos-Peleja, Nuria ; Santos, Juliana Carvalho ; Armengol, Marc ; Fernández-Serrano, Miranda ; Sedo Mor, Alicia ; Bech-Serra, Joan Josep ; Bledua, Pedro ; Musulen, Eva ; De La Torre, Carolina ; Miskin, Hari P. ; Esteller, Manel ; Bosch, Francesc ; Menéndez, Pablo ; Normant, Emmanuel ; Roué, Gaël
Programa/Curso (s)	Programa de Pós-Graduação Stricto Sensu em Ciências da Saúde
DOI	10.1158/1078-0432.CCR-21-1067
Assunto (palavras chaves)	BTK, TG1701, Ikaros, B-cell non-Hodgkin lymphoma
Idioma	Inglês
Fonte	Título do periódico: Clin Cancer Res ISSN: 1557-3265 Volume/Número/Paginação/Ano: ;27(23):6591-6601/2021
Data da publicação	2021 Dec 1
Formato da produção	Digital
Resumo	<p>Purpose: Despite the remarkable activity of BTK inhibitors (BTKi) in relapsed B-cell non-Hodgkin lymphoma (B-NHL), no clinically-relevant biomarker has been associated to these agents so far. The relevance of phosphoproteomic profiling for the early identification of BTKi responders remains underexplored.</p> <p>Experimental design: A set of six clinical samples from an ongoing phase I trial dosing patients with chronic lymphocytic leukemia (CLL) with TG-1701, a novel irreversible and highly specific BTKi, were characterized by phosphoproteomic and RNA sequencing (RNA-seq) analysis. The activity of TG-1701 was evaluated in a panel of 11 B-NHL cell lines and mouse xenografts, including two NF-KB- and BTKC481S-driven BTKi-resistant models. Biomarker validation and signal transduction analysis were conducted through real-time PCR, Western blot analysis, immunostaining, and gene knockout (KO) experiments.</p> <p>Results: A nonsupervised, phosphoproteomic-based clustering did match the early clinical outcomes of patients with CLL and separated a group of "early-responders" from a group of "late-responders." This clustering was based on a selected list of 96 phosphosites with Ikaros-pSer442/445 as a potential biomarker for TG-1701 efficacy. TG-1701 treatment was further shown to blunt Ikaros gene signature, including YES1 and MYC, in early-responder patients as well as in BTKi-sensitive B-NHL cell lines and</p>



xenografts. In contrast, Ikaros nuclear activity and signaling remained unaffected by the drug in vitro and in vivo in late-responder patients and in BTKC481S, BTKKO, and noncanonical NF- κ B models.

Conclusions: These data validate phosphoproteomic as a valuable tool for the early detection of response to BTK inhibition in the clinic, and for the determination of drug mechanism of action.

Fomento